← Back to Search

Peer Mentorship for Sickle Cell Disease

N/A

Waitlist Available

Research Sponsored by The Hospital for Sick Children

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will assess the feasibility and preliminary effectiveness of peer mentorship for youth with sickle cell disease.

Who is the study for?

This trial is for English-speaking youths aged 12-18 with Sickle Cell Disease who have internet access and can use Skype. They should be diagnosed by a hematologist and willing to complete online measures. Those with major illnesses or cognitive impairments, or in other peer support programs cannot join.

What is being tested?

The iPeer2Peer program pairs young SCD patients with mentors who manage their condition well. Over 15 weeks, the intervention group will have up to ten calls with their mentor, while the control group waits for a mentor. The study aims to see if this is doable and how it affects health outcomes.

What are the potential side effects?

Since this trial involves mentorship rather than medication, there are no direct medical side effects expected. However, participants may experience emotional or social discomfort during interactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of iPeer2Peer SCD intervention

Rates of completion of mentor-mentee calls

Recruitment Rate

+1 more

Secondary study objectives

PROMIS Pain Interference - 8a

Anxiety

PROMIS depressive symptoms - 8a

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: iPeer2Peer MentorshipExperimental Treatment1 Intervention

In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.

Group II: Waitlist Control GroupActive Control1 Intervention

The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

iPeer2Peer Mentorship

2017

N/A

~170

Do I qualify?Apply below to find out